Aflibercept administration in neovascular age-related macular degeneration refractory to previous anti-vascular endothelial growth factor drugs: a critical review and new possible approaches to move forward

Angiogenesis

Volumn 18, Issue 4, 2015, Pages 397-432

  Lazzeri, Stefano ^a,b   Ripandelli, Guido ^b   Sartini, Maria Sole ^a   Parravano, Mariacristina ^b   Varano, Monica ^b   Nardi, Marco ^a   Di Desidero, Teresa ^a   Orlandi, Paola ^a   Bocci, Guido ^a  

^a UNIVERSITY OF PISA   (Italy)

^b IRCCS FONDAZIONE BIETTI   (Italy)

Author keywords

Aflibercept; Anti VEGF drug; Intravitreal injections; Recurrent exudative AMD; Resistant wet AMD

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; PEGAPTANIB; RANIBIZUMAB; TRIAMCINOLONE; VASCULOTROPIN; HYBRID PROTEIN; VASCULOTROPIN RECEPTOR;

ACUTE HEART INFARCTION; AGE RELATED MACULAR DEGENERATION; ARTERIAL THROMBOEMBOLISM; ATRIAL FIBRILLATION; CATARACT; CENTRAL MACULAR THICKNESS; CLINICAL TRIAL (TOPIC); CONJUNCTIVAL HEMORRHAGE; DEEP VEIN THROMBOSIS; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOPHTHALMITIS; EYE INFLAMMATION; FAINTNESS; GASTRITIS; GEOGRAPHIC ATROPHY; HUMAN; LOADING DRUG DOSE; NEOVASCULAR AGE RELATED MACULAR DEGENERATION; PHOTODYNAMIC THERAPY; PNEUMONIA; PRIORITY JOURNAL; PROSPECTIVE STUDY; RETINA DETACHMENT; RETINA MACULA HEMORRHAGE; RETINA TEAR; RETROSPECTIVE STUDY; REVIEW; SIDE EFFECT; SPONDYLOLISTHESIS; SUBRETINAL FLUID; SYSTEMATIC REVIEW; TACHYPHYLAXIS; TREATMENT OUTCOME; UVEITIS; VISUAL ACUITY; VITREOUS HEMORRHAGE; CHOROIDAL NEOVASCULARIZATION; DRUG EFFECTS; DRUG RESISTANCE; METABOLISM; PATHOLOGY; WET MACULAR DEGENERATION;

CHOROIDAL NEOVASCULARIZATION; DRUG RESISTANCE; HUMANS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; RECOMBINANT FUSION PROTEINS; WET MACULAR DEGENERATION;

EID: 84943351924     PISSN: 09696970     EISSN: 15737209     Source Type: Journal    
DOI: 10.1007/s10456-015-9483-4     Document Type: Review

References (85)

1. Friedman DS, O’Colmain BJ, Munoz B et al (2004) Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 122:564–572
2. Khandhadia S, Cherry J, Lotery AJ (2012) Age-related macular degeneration. Adv Exp Med Bio 724:15–36
3. Rosenfeld PJ, Brown DM, Heier JS et al (2006) Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 355:1419–1431
4. Brown DM, Kaiser PK, Michels M et al (2006) Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 355:1432–1444
5. Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group, Martin DF, Maguire MG et al (2012) Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 119:1388–1398
6. CATT Research Group (2011) Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 364:1897–1908
7. Heier JS, Brown DM, Chong V et al (2012) VIEW 1 and VIEW 2 Study Groups. Intravitreal aflibercept (VEGF Trap-Eye) in wet age-related macular degeneration. Ophthalmology 119:2537–2548
8. Dorrell M, Uusitalo-Jarvinen H, Aguilar E et al (2007) Ocular neovascularization: basic mechanisms and therapeutic advances. Surv Ophthalmol 52(suppl 1):S3–S19
9. Stewart MW, Rosenfeld PJ (2008) Predicted biological activity of intravitreal VEGF Trap. Br J Ophthalmol 92:667–668
10. Stewart MW (2012) Clinical and differential utility of VEGF inhibitors in wet age-related macular degeneration: focus on aflibercept. Clin Ophthalmol 6:1175–1186
11. Papadopoulos N, Martin J, Ruan Q et al (2012) Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab. Angiogenesis 15:171–185
12. Schmidt-Erfurth U, Kaiser PK, Korobelnik JF et al (2014) Intravitreal aflibercept injection for neovascular age-related macular degeneration: ninety-six-week results of the VIEW studies. Ophthalmology 121:193–201
13. Rofagha S, Bhisitkul RB, Boyer DS, Sadda SR, Zhang K, SEVEN-UP Study Group (2013) Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology 120:2292–2299
14. Binder S (2012) Loss of reactivity in intravitreal anti-VEGF therapy: tachyphylaxis or tolerance? Br J Ophthalmol 96:1–2
15. Eghøj MS, Sørensen TL (2012) Tachyphylaxis during treatment of exudative age-related macular degeneration with ranibizumab. Br J Ophthalmol 96:21–23
16. Schaal S, Kaplan HJ, Tezel TH (2008) Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology 115:2199–2205
17. Fooroghian F, Cukras C, Meyerle CB et al (2009) Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina 29:723–731
18. Hoffman BB, Taylor P (2001) Neurotransmission: the autonomic and somatic motor nervous systems. In: Hardman JG, Limbird LE, Gilman AG (eds) Goodman and Gilman’s the pharmacological basis of therapeutics, 10th edn. McGraw-Hill, New York, pp 115–154
19. Tranos P, Vacalis A, Asteriadis S et al (2013) Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration. Drug Des Devel Ther 7:485–490
20. Gasperini JL, Fawzi AA, Khondkaryan A et al (2012) Bevacizumab and ranibizumab tachyphylaxis in the treatment of choroidal neovascularization. Br J Ophthalmol 96:14–20
21. Brown DM, Chen E, Mariani A et al (2013) Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration: primary end point. Ophthalmology 120:349–354
22. Fung AT, Kumar N, Vance SK et al (2012) Pilot study to evaluate the role of high-dose ranibizumab 2.0 mg in the management of neovascular age-related macular degeneration in patients with persistent/recurrent macular fluid <30 days following treatment with intravitreal anti-VEGF therapy (the LAST Study). Eye 26:1181–1187
23. Chaikitmongkol V, Bressler NM (2013) Dramatic resolution of choroidal neovascular abnormalities after single aflibercept injection following years of ranibizumab use. JAMA Ophthalmol 131:260–262
24. Miura M, Iwasaki T, Goto H (2013) Intravitreal aflibercept for polypoidal choroidal vasculopathy after developing ranibizumab tachyphylaxis. Clin Ophthalmol 7:1591–1595
25. Yonekawa Y (2013) Aflibercept for the treatment of refractory polypoidal choroidal vasculopathy. Can J Ophthalmol 48:e59–e60
26. Yamashita M, Nishi T, Hasegawa T et al (2014) Response of serous retinal pigment epithelial detachments to intravitreal aflibercept in polypoidal choroidal vasculopathy refractory to ranibizumab. Clin Ophthalmol 2:343–346
27. Saito M, Kano M, Itagaki K et al (2014) Switching to intravitreal aflibercept injection for polypoidal choroidal vasculopathy refractory to ranibizumab. Retina 34:2192–2201
28. Imamura Y, Engelbert M, Iida T et al (2010) Polypoidal choroidal vasculopathy: a review. Surv Ophthalmol 55:501–505
29. Okubo A, Ito M, Sameshima M et al (2005) Pulsatile blood flow in the polypoidal choroidal vasculopathy. Ophthalmology 112:1436–1441
30. Maruko I, Iida T, Saito M et al (2007) Clinical characteristics of exudative age-related macular degeneration in Japanese patients. Am J Ophthalmol 144:15–22
31. Sasahara M, Tsujikawa A, Musashi K et al (2006) Polypoidal choroidal vasculopathy with choroidal vascular hyperpermeability. Am J Ophthalmol 142:601–607
32. Okubo A, Hirakawa M, Ito M et al (2008) Clinical features of early and late stage polypoidal choroidal vasculopathy characterized by lesion size and disease duration. Graefes Arch Clin Exp Ophthalmol 246:491–499
33. Laude A, Cackett PD, Vithana EN et al (2010) Polypoidal choroidal vasculopathy and neovascular age-related macular degeneration: same or different disease? Prog Retina Eye Res 29:19–29
34. Matsumiya W, Honda S, Bessho H, et al (2011). Early responses to intravitreal ranibizumab in typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. J Ophthalmic 742020
35. Ruamviboonsuk P, Tadarati M, Vanichvaranont S et al (2010) Photodynamic therapy combined with ranibizumab for polypoidal choroidal vasculopathy: results of a 1-year preliminary study. Br J Ophthalmol 94:1045–1051
36. Sonoda S, Sakamoto T, Otsuka H et al (2013) Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab. BMC Ophthalmol 13:43
37. Ho VY, Yeh S, Olsen TW et al (2013) Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors. Am J Ophthalmol 156:23–28
38. Kumar N, Marsiglia M, Mrejen S et al (2013) Visual and anatomical outcomes of intravitreal aflibercept in eyes with persistent subfoveal fluid despite previous treatments with ranibizumab in patients with neovascular age-related macular degeneration. Retina 33:1605–1612
39. Grewal DS, Gill MK, Sarezky D et al (2014) Visual and anatomical outcomes following intravitreal aflibercept in eyes with recalcitrant neovascular age-related macular degeneration: 12-month results. Eye 28:895–899
40. Yonekawa Y, Andreoli C, Miller JB et al (2013) Conversion to aflibercept for chronic refractory or recurrent neovascular age-related macular degeneration. Am J Ophthalmol 156:29–35
41. Kawashima Y, Oishi A, Tsujikawa A, et (2014). Effects of aflibercept for ranibizumab-resistant neovascular age-related macular degeneration and polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol. 2014 [Epud ahead of print]
42. Fujii A, Imai H, Kanai M et al (2014) Effect of intravitreal aflibercept injection for age-related macular degeneration with retinal pigment epithelial tear refractory to intravitreal ranibizumab injection. Clin Ophthalmol 24:1199–1202
43. Hanh P (2014) Successful treatment of neovascular age-related macular degeneration following single bevacizumab failure using aflibercept in a vitrectomized eye. Clin Ophthalmol 17:2129–2131
44. Rusu IM, Deobhakta A, Yoon D et al (2014) Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments. Retina 34:2161–2166
45. Broadhead GK, Hong T, Zhu M, et al (2015). Response of pigment epithelial detachments to intravitreal aflibercept among patients with treatment-resistant neovascular age-related macular degeneration. Retina [Epud ahead of print]
46. de Oliveira Dias JR, Xavier CO, Maia A et al (2015) Intravitreal injection of ziv-aflibercept in patient with refractory age-related macular degeneration. Ophthalmic Surg Lasers Imaging. Retina. 46:91–94
47. Patel KH, Chow CC, Rathod R et al (2013) Rapid response of retinal pigment epithelial detachments to intravitreal aflibercept in neovascular age-related macular degeneration refractory to bevacizumab and ranibizumab. Eye 27:663–667
48. Bakall B, Folk JC, Boldt HC et al (2013) Aflibercept therapy for exudative age-related macular degeneration resistant to bevacizumab and ranibizumab. Am J Ophthalmol 156:15–22
49. Heussen FM, Shao Q, Ouyang Y, et al (2013). Clinical outcomes after switching treatment from intravitreal ranibizumab to aflibercept in neovascular age-related macular degeneration. Graefes Arch Clin Exp Ophthalmol [Epub ahead of print]
50. Cho H, Shah CP, Weber M et al (2013) Aflibercept for exudative AMD with persistent fluid on ranibizumab and/or bevacizumab. Br J Ophthalmol 97:1032–1035
51. Fassnacht-Riederle H, Becker M, Graf N, et al (2014). Effect of aflibercept in insufficient responders to prior anti-VEGF therapy in neovascular AMD. Graefes Arch Clin Exp. Ophthalmol [Epub ahead of print]
52. Hall LB, Zebardast N, Huang JJ, et al (2014). Aflibercept in the Treatment of Neovascular Age-Related Macular Degeneration in Previously Treated Patients. J Ocul Pharmacol Ther [Epub ahead of print]
53. Messenger WB, Campbell JP, Faridi A et al (2014) Injection frequency and anatomic outcomes 1 year following conversion to aflibercept in patients with neovascular age-related macular degeneration. Br J Ophthalmol 98:1205–1207
54. Gharbiya M, Iannetti L, Parisi F et al (2014) Visual and anatomical outcomes of intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Biomed Res Int 2014:273754
55. Arcinue CA, Ma F, Barteselli G, Sharpsten L et al (2015) One-year outcomes of aflibercept in recurrent or persistent neovascular age-related macular degeneration. Am J Ophthalmol 159:426–436
56. Griffin DR, Richmond PP, Olson JC (2014) Intravitreal aflibercept outcomes in patients with persistent macular exudate previously treated with bevacizumab and/or ranibizumab for neovascular age-related macular degeneration. J Ophthalmol 2014:497178
57. Thorell MR, Nunes RP, Chen GW et al (2014) Response to aflibercept after frequent re-treatment with bevacizumab or ranibizumab in eyes with neovascular AMD. Ophthalmic Surg Lasers Imaging Retina 45:526–533
58. Eadie JA, Gottlieb JL, Ip MS et al (2014) Response to aflibercept in patients with persistent exudation despite prior treatment with bevacizumab or ranibizumab for age-related macular degeneration. Ophthalmic Surg Lasers Imaging Retina 45:394–397
59. Michalewski J, Nawrocki J, Trębińska M et al (2014) Switch to a single dose of aflibercept in bevacizumab nonresponders with AMD. Can J Ophthalmol 49:431–435
60. Wykoff CC, Brown DM, Maldonado ME, et al (2014). Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial). Br J Ophthalmol [Epub ahead of print]
61. Chang AA, Li H, Broadhead GK et al (2014) Intravitreal aflibercept for treatment-resistant neovascular age-related macular degeneration. Ophthalmology 121:188–192
62. Singh RP, Srivastava S, Ehlers JP et al (2014) A single-arm, investigator-initiated study of the efficacy, safety and tolerability of intravitreal aflibercept injection in subjects with exudative age-related macular degeneration, previously treated with ranibizumab or bevacizumab: 6-month interim analysis. Br J Ophthalmol 98(Suppl 1):i22–i27
63. Lazzeri S, Nardi M, Bocci G (2013) Pharmacogenetic labyrinth of neovascular age-related macular degeneration therapy: how to escape and move forward? Pharmacogenomics 14:1239–1242
64. Chong V (2012) Biological, preclinical and clinical characteristics of inhibi-tors of vascular endothelial growth factors. Ophthalmologica 227(Suppl 1):2–10
65. Browning DJ, Kaiser PK, Rosenfeld PJ et al (2012) Aflibercept for age-related macular degeneration: a game-changer or quiet addition? Am J Ophthalmol 154:222–226
66. Schmidt-Erfurth U, Eldem B, Guymer R, EXCITE Study Group et al (2011) Efficacy and safety of monthly versus quarterly ranibizumab treatment in neovascular age-related macular degeneration: the EXCITE study. Ophthalmology 118:831–839
67. Funk M, Karl D, Georgopoulos M et al (2009) Neovascular age-related macular degeneration: intraocular cytokines and growth factors and the influence of therapy with ranibizumab. Ophthalmology 116:2393–2399
68. Lai TY, Liu DT, Chan KP et al (2009) Visual outcomes and growth factor changes of two dosages of intravitreal bevacizumab for neovascular age-related macular degeneration: a randomized, controlled trial. Retina 29:1218–1226
69. Meier CH, Krohne TU, Holz FG (2011) Intraocular pharmacokinetics after a single intravitreal injection of 1.5 mg versus 3.0 mg of bevacizumab in humans. Retina 31:1877–1884
70. Busbee BG, Ho AC, Brown DM et al (2013) Twelve-month efficacy and safety of 0.5 or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 120:1046–1056
71. Stewart MW, Rosenfeld PJ, Penha FM et al (2012) Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab and aflibercept (vascular endothelial growth factor Trap-eye). Retina 32:434–457
72. Forooghian F, Chew EY, Meyerle CB et al (2011) Investigation of the role of neutralizing antibodies against bevacizumab as mediators of tachyphylaxis. Acta Ophthalmol 89:e206–e207
73. Zhang F, Tang Z, Hou X et al (2009) VEGF-B is dispensable for blood vessel growth but critical for their survival, and VEGF-B targeting inhibits pathological angiogenesis. Proc Natl Acad Sci USA 106:6152–6157
74. Rakic JM, Lambert V, Devy L et al (2003) Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3186–3193
75. Grossniklaus HE, Ling JX, Wallace TM et al (2002) Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol Vis 8:119–126
76. Espinosa-Heidmann DG, Suner IJ, Hernandez P et al (2003) Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3586–3592
77. Sakurai E, Anand A, Ambati BK et al (2003) Macrophage depletion inhibits experimental choroidal neovascularization. Invest Ophthalmol Vis Sci 44:3578–3585
78. Leveziel N, Pelat T, Watier H et al (2013). Detection of anti-ranibizumab antibodies among exudative AMD patients. Association for Research in Vision and Ophthalmology (ARVO) Meeting. Seattle, WA, USA, 5–9 May 2013 (Abstract 3170)
79. Bressler NM (2004) Age-related macular degeneration is the leading cause of blindness. JAMA 291:1900–1901
80. Wickremasinghe SS, Michalova K, Gilhotra J et al (2008) Acute intraocular inflammation after intravitreous injections of bevacizumab for treatment of neovascular age-related macular degeneration. Ophthalmology 115:1911–1915
81. Lazzeri S, Figus M, Orlandi P et al (2013) VEGF-A polymorphisms predict short-term functional response to intravitreal ranibizumab in exudative age-related macular degeneration. Pharmacogenomics 14:623–630
82. Agosta E, Lazzeri S, Orlandi P et al (2012) Pharmacogenetics of antiangiogenic and antineovascular therapies of age-related macular degeneration. Pharmacogenomics 13:1037–1053
83. Kitchens JW, Kassem N, Wood W et al (2013) A pharmacogenetics study to predict outcome in patients receiving anti-VEGF therapy in age related macular degeneration. Clin Ophthalmol 7:1987–1993
84. Park UC, Shin JY, Kim SJ et al (2014) Genetic factors associated with response to intravitreal ranibizumab in Korean patients with neovascular age-related macular degeneration. Retina 34:288–297
85. Park UC, Shin JY, McCarthy LC et al (2014) Pharmacogenetic associations with long-term response to anti-vascular endothelial growth factor treatment in neovascular AMD patients. Mol Vis 20:1680–1694